Clinical Trial Update: SAD/MAD Study of a New Formulation of Nebulised RPL554 in Healthy Subjects and COPD Subjects [Phase 1]

View source ↗

Summary

This trial update reports the completion of a Phase 1 SAD/MAD study of a new nebulised formulation of RPL554 in healthy subjects and COPD subjects.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• RPL554 (RPL554)

Snippet

Sponsor: Verona Pharma plc | Conditions: Inflammatory Disorder of the Respiratory Tract, Chronic Obstructive Pulmonary Disorder | Phase 1 | Status: COMPLETED